Femasys Inc. (FEMY)
| Market Cap | 8.03M -73.5% |
| Revenue (ttm) | 2.38M +39.9% |
| Net Income | -12.40M |
| EPS | -5.01 |
| Shares Out | 3.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,091,224 |
| Open | 3.110 |
| Previous Close | 2.950 |
| Day's Range | 2.291 - 3.138 |
| 52-Week Range | 2.291 - 22.200 |
| Beta | -2.09 |
| Analysts | Buy |
| Price Target | 63.33 (+2,280.83%) |
| Earnings Date | Aug 14, 2026 |
About FEMY
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women’s reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It ... [Read more]
Financial Performance
In 2025, Femasys's revenue was $2.29 million, an increase of 40.77% compared to the previous year's $1.63 million. Losses were -$18.63 million, -1.00% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for FEMY stock is "Buy." The 12-month stock price target is $63.33, which is an increase of 2,280.83% from the latest price.
News
Femasys announces $30M private placement
Femasys (FEMY) announced that it has entered into a securities purchase agreement for a $30M private placement with certain accredited investors. The financing was led by new institutional investor Na...
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
-- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transf...
Femasys regains compliance with Nasdaq
Femasys (FEMY) announced that it received formal notice from Nasdaq confirming the company has regained compliance with Listing Rule 5550, the minimum bid price requirement for continued listing and t...
Femasys Regains Compliance with Nasdaq Listing Requirements
ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-eff...
Femasys Inc trading halted, news pending
19:50 EDT Femasys (FEMY) Inc trading halted, news pending
Femasys announces CE Mark approval for FemHSG Catheter
Femasys (FEMY) announced CE Mark approval for its FemHSG Catheter, further expanding the company’s portfolio in Europe through commercial partners.
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
-- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --
Femasys Slides: Corporate presentation
Femasys has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- -- With fertili...
Femasys Quarterly report: Q1 2026
Femasys has published its Q1 2026 quarterly earnings report on May 8, 2026.
Femasys Earnings release: Q1 2026
Femasys released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femas...
Femasys Proxy statement: Proxy filing
Femasys filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Femasys Proxy statement: Proxy filing
Femasys filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Femasys drives growth with Israeli market entry for fertility portfolio
Femasys (FEMY) announced a strategic partnership with AMI Technologies to introduce and commercialize its fertility portfolio in Israel. This collaboration marks an important step in the Company’s glo...
Femasys Proxy statement: Proxy filing
Femasys filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execu...
Femasys Annual report: Q4 2025
Femasys has published its Q4 2025 annual report on March 31, 2026.
Femasys Earnings release: Q4 2025
Femasys released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Femasys Proxy statement: Proxy filing
Femasys filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Femasys management to meet virtually with Lake Street
Virtual Meeting to be held on March 26 hosted by Lake Street.
Femasys appoints Kenneth Eichenbaum to its Board of Directors
Femasys (FEMY) announced the appointment of Kenneth D. Eichenbaum, to its Board of Directors. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Bea...
Femasys advances FemBloc to U.S. approval with initiation of trial enrollment
Femasys (FEMY) announced the initiation of patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc. This milestone follows U.S. Food and Drug Administration, FDA, Investigational De...
Femasys initiated with a Buy at Lake Street
Lake Street analyst Ben Haynor initiated coverage of Femasys (FEMY) with a Buy rating and $1.50 price target FemBloc is the first and only non-surgical alternative that can be performed…
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to w...